PMID- 38310863
OWN - NLM
STAT- Publisher
LR  - 20240204
IS  - 1423-0399 (Electronic)
IS  - 0042-1138 (Linking)
DP  - 2024 Feb 2
TI  - Sunitinib for metastatic renal cell carcinoma: Real world data from the STAR-TOR 
      registry and detailed literature review.
LID - 10.1159/000536563 [doi]
AB  - INTRODUCTION: We evaluated the effectiveness and safety profile of the tyrosine 
      kinase inhibitor Sunitinib in patients with advanced or metastatic renal cell 
      carcinoma (a/mRCC) in a real-world setting. METHODS: We analyzed data of adult 
      a/mRCC patients treated with Sunitinib. Data was derived from the German 
      non-interventional post-approval multicenter STAR-TOR registry (NCT00700258). 
      Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) 
      were evaluated using descriptive statistics and survival analyses for the entire 
      cohort and patient subgroups. RESULTS: A total of 116 study sites recruited 702 
      patients treated with Sunitinib (73.1% male; median age 68.0 years; median 
      Karnofsky Index 90%) between November 2010 and May 2020. The most frequent 
      histological subtype was clear cell RCC (ccRCC) (81.6%). Sunitinib was 
      administered as first-line treatment in 83.5%, as second line in 11.7%, and as 
      third line or beyond in 4.8% of the patients. Drug related AEs and serious AEs 
      were reported in 66.3% and 13.9% of the patients, respectively (most common AE: 
      gastrointestinal disorders; 39.7% of all patients). CONCLUSIONS: This study adds 
      further real-world evidence of the persisting relevance of Sunitinib for patients 
      with a/mRCC who cannot receive or tolerate immune checkpoint inhibitors. The 
      study population includes a high proportion of patients with unfavorable MSKCC 
      poor-risk score, but shows still good PFS and OS results, while the drug 
      demonstrates a favorable safety profile.
CI  - S. Karger AG, Basel.
FAU - Uhlig, Annemarie
AU  - Uhlig A
FAU - Bergmann, Lothar
AU  - Bergmann L
FAU - Bogemann, Martin
AU  - Bogemann M
FAU - Fischer, Thomas
AU  - Fischer T
FAU - Goebell, Peter J
AU  - Goebell PJ
FAU - Leitsmann, Marianne
AU  - Leitsmann M
FAU - Reichert, Mathias
AU  - Reichert M
FAU - Rink, Michael
AU  - Rink M
FAU - Schlack, Katrin
AU  - Schlack K
FAU - Trojan, Lutz
AU  - Trojan L
FAU - Uhlig, Johannes
AU  - Uhlig J
FAU - Woike, Michael
AU  - Woike M
FAU - Strauss, Arne
AU  - Strauss A
LA  - eng
PT  - Journal Article
DEP - 20240202
PL  - Switzerland
TA  - Urol Int
JT  - Urologia internationalis
JID - 0417373
SB  - IM
EDAT- 2024/02/05 00:42
MHDA- 2024/02/05 00:42
CRDT- 2024/02/04 18:27
PHST- 2023/08/03 00:00 [received]
PHST- 2024/01/15 00:00 [accepted]
PHST- 2024/02/05 00:42 [medline]
PHST- 2024/02/05 00:42 [pubmed]
PHST- 2024/02/04 18:27 [entrez]
AID - 000536563 [pii]
AID - 10.1159/000536563 [doi]
PST - aheadofprint
SO  - Urol Int. 2024 Feb 2. doi: 10.1159/000536563.